The decade ahead will test our healthcare system like never before. But within these challenges lies an opportunity to create a more accessible, effective, and sustainable healthcare system — if we dare to innovate and adapt to the changing landscape. The post How Technology and Value-Based Models Will Reshape Healthcare by 2035 appeared first on…
By moving beyond adherence and drug interactions to a holistic, outcomes-driven approach, health systems and providers can redefine how medication is used — not as a rigid protocol but as a dynamic, patient-centered tool for achieving better health. The post Medication Adherence and Deprescribing Programs Aren’t Enough for Today’s Polypharmacy Patients appeared first on MedCity…
Cigna Healthcare ranks highest among commercial health plans when it comes to digital experience, while UPMC Health Plan ranks highest among Medicare Advantage plans, according to J.D. Power. The post Which Health Plans Take the Lead in Member Digital Experience? appeared first on MedCity News.
The combination of Bristol Myers Squibb cancer drugs Opdivo and Yervoy landed FDA approvals for the first-line treatment of colorectal cancer and hepatocellular carcinoma. Several other products also expanded their approved uses in our recap of recent regulatory news. The post BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a…
Even as studies and personal experiences repeatedly reflect the effectiveness of MOUD, a stigma about this approach and the medication persists, complicating efforts to help more people treat their opioid use disorders. The post Stigma Against Addiction Medication Limits Our Ability to End the Opioid Epidemic appeared first on MedCity News.
At Medicarians 2025, MedCity News Editor-in-Chief Arundhati Parmar explored the state of AgeTech venture capital with three investors. The panelists agreed that despite growing clear opportunities, the AgeTech market currently lacks the dedicated funding, proven business models and major success stories needed for it to take off. The post Where Does AgeTech Investment Stand?: VCs…
The goal of the Two-Midnight Rule, originally introduced under traditional Medicare Part A, was to reduce hospital admissions and to ensure the appropriate use of inpatient versus outpatient observation status. Here are some challenges and best practices. The post Navigating Medicare Advantage Compliance One Year After the Two-Midnight Rule appeared first on MedCity News.
CMS recently announced that payments to Medicare Advantage plans will increase by 5.06%, drawing support from payer advocates. The post Payer Advocates Applaud 5% MA Payment Increase appeared first on MedCity News.
Healthcare staff are finding Artera’s AI agents helpful and easy to use after six months of real-world deployment. One of these copilots helps staff manage patient communications faster and more accurately, and the other gives providers access to data to better tailor their patient outreach efforts. The post Why 100+ Providers Are Using Artera’s AI…
The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab-on-a-chip tests, the agency is encouraging drug companies to use computer simulations and artificial intelligence to predict drug behavior. The post FDA Phase Out of Animal Test Requirements for Drugs Begins With Biologics appeared…